Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation.

Molecular medicine reports

PubMedID: 25060817

Zhou DY, Ding N, Du ZY, Cui XX, Wang H, Wei XC, Conney AH, Zhang K, Zheng X. Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation. Mol Med Rep. 2014;10(3):1315-22.
The androgen receptor (AR) has a critical role in prostate cancer development and progression. Several curcumin analogues (A10, B10, C10, E10 and F10) with different linker groups were investigated for their effects in human prostate cancer CWR-22Rv1 and LNCaP cell lines. The ability of these compounds to inhibit testosterone (TT)- or dihydrotestosterone (DHT)-induced AR activity was determined by an AR-linked luciferase assay and by TT- or DHT-induced expression of prostate specific antigen. Compounds F10 and E10 had stronger inhibitory effects on the growth of cultured CWR-22Rv1 and LNCaP cell lines, and they also had enhanced stimulatory effects on apoptosis compared with curcumin and other curcumin analogues (A10, B10, C10) in CWR-22Rv1 cells. E10 and F10 were more potent inhibitors of AR activity than curcumin, A10 and B10. The higher activities of E10 and F10 may be correlated with a heteroatom linker. The results indicate that one of the potential mechanisms for the anticancer effect of the curcumin analogues was inhibition of AR pathways in human prostate cancer cells.